IL17A and neoplasm: Moreover, the Nb‐CAR.BiTE‐engineered γδT cells did not secrete IL‐17A, even after engaging with tumor cells (Figure 3F), suggesting that their potential protumor effect could be ruled out.[52] Accordingly, this Nb‐CAR.BiTE‐γδT therapy likely has broad clinical applicability.